Polaryx Therapeutics (NASDAQ:PLYX) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Polaryx Therapeutics from “sell” to “hold.” Other analysts are more optimistic, and the company has a consensus “Moderate Buy” rating with an average price target of $7.67.
• PLYX shares opened at $2.01, with a market capitalization of approximately $100.2 million. The stock is trading near its 52-week low of $1.85, versus a high of $48.91.
• Polaryx reported a quarterly loss of $0.03 per share, beating the consensus estimate of a $0.05 loss. Analysts expect a full-year loss of approximately $0.22 per share.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also commented on PLYX. HC Wainwright began coverage on shares of Polaryx Therapeutics in a research report on Thursday, July 9th. They issued a "buy" rating and a $7.00 price target on the stock. Weiss Ratings raised shares of Polaryx Therapeutics from a "sell (e-)" rating to a "sell (e)" rating in a research report on Wednesday, July 1st. Zacks Research raised shares of Polaryx Therapeutics to a "hold" rating in a research note on Friday, July 10th. Finally, Raymond James Financial initiated coverage on shares of Polaryx Therapeutics in a research report on Thursday, August 13th. They set a "strong-buy" rating and a $6.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.67.

Polaryx Therapeutics Stock Up 1.0%

NASDAQ:PLYX opened at $2.01 on Friday. The stock has a market cap of $100.20 million and a PE ratio of -25.12. Polaryx Therapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $48.91. The firm's fifty day simple moving average is $2.18 and its 200-day simple moving average is $3.44.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. Equities analysts anticipate that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.